Why wait? The FDA stamps an ultra-fast OK on a HER2+ drug expected to create AstraZeneca’s next blockbuster franchise

The FDA isn’t playing any waiting games when it comes to hustling up a quick OK for a breakthrough cancer drug. In what has to be the fastest culmination of one of the smoothest multi-billion dollar alliances in biopharma history, the agency stamped their seal of marketing approval on trastuzumab

Read the full article here

Related Articles